WWL113
CAS No. : 947669-86-5
| Size | Price | Stock |
|---|---|---|
| 5mg | $80 | In-stock |
| 10mg | $140 | In-stock |
| 25mg | $300 | In-stock |
| 50mg | $510 | In-stock |
| 100mg | $810 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-110148 |
| M.Wt: | 466.53 |
| Formula: | C29H26N2O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 20.83 mg/mL (ultrasonic;warming;heat to 60°C) |
WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC50 values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases)[1].
IC50 & Target: IC50: 120 nM (Ces3), 100 nM (Ces1f)[1].
In Vitro: Ces3 and Ces1f are endoplasmic reticulum glycoproteins that have been previously associated with adipocyte lipolysis. WWL113 inhibits mouse recombinant Ces1, Ces1c, and ABHD6 at 10 μM[1].
WWL113 (1 μM) significantly increases UCP1 protein expression in brown adipocytes[2].
WWL113 has a partial, statistically significant inhibitory effect on blocking the buildup of PGE2[3].
In Vivo: WWL113 (30 mg/kg, orally once a day) results in major improvement of multiple features of metabolic syndrome and ameliorated obesity-diabetes in mice with lowered levels of nonesterified free fatty acids (NEFAs), triglycerides (TGs), total cholesterol and fasted glucose as well as enhanced glucose tolerance[1].
WWL113 ameliorates obesity-diabetes in mice[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- WWL113
- Cat. No.:
- HY-110148
- Quantity:
Your information is safe with us.